throbber

`
`
`
`
`
`
`TECHNICAL DATA SHEET
`TDS-730
`Edition: August 13, 2010
`Original Date: November 24, 2009 / January 27, 2010
`
`
`Viscosity of Carbopol®* Polymers in
`Aqueous Systems
`
`Introduction
`Carbopol® polymers can be used to develop semisolid and oral liquid formulations with a wide range of flow
`and rheological properties (Figure 1). The polymers are highly efficient thickeners, suspending agents and
`stabilizers at low usage levels (0.1 - 3.0 wt%).
`
`Figure 1: Flow Properties of Carbopol® Polymers, Neutralized Dispersions
`
`
`
`
`
`
`
`
`Low
`Long (Pourable)
`
`Polymer Crosslink Density: High/Medium
` Short
`Flow Property:
`
`
`All Carbopol® polymers are high molecular weight, crosslinked polyacrylic acid polymers. The main
`differences among the polymers are the crosslinker type and density and solvent used to synthesize the
`polymer. A description of the polymers featured in this document is shown in Tables 1A and 1B. Please
`refer to Bulletin 1- Polymers for Pharmaceutical Applications for a complete list of polymers.
`
`
`Table 1A: Carbopol® Polymers Overview
`
`Carbopol®
`Polymer Type Crosslink
`Polymerization
`Recommended
`Density
`Solvent
`Applications
`Polymer
`Homopolymer
`Low
`Ethyl Acetate
`Oral / Topical
`971P NF
`Homopolymer
`Medium
`Ethyl Acetate
`Oral / Topical
`974P NF
`Cosolvent1
`Homopolymer
`High
`Topical
`980 NF
`Homopolymer
`Medium
`Cosolvent
`Topical
`5984 EP
`Interpolymer
`Medium
`Cosolvent
`Topical
`ETD 2020 NF
`Interpolymer
`High
`Cosolvent
`Topical
`Ultrez 10 NF
`1 Cosolvent is a mixture of ethyl acetate and cyclohexane.
`
`
`Lubrizol Advanced Materials, Inc. / 9911 Brecksville Road, Cleveland, Ohio 44141-3247 / TEL: 800.379.5389 or 216.447.5000Lubrizol Advanced Materials, Inc. / 9911 Brecksville Road, Cleveland, Ohio 44141-3247 / TEL: 800.379.5389 or 216.447.5000
`
`The information contained herein is believed to be The information contained herein is believed to be
`
`Materials, Inc.’s direct control. THE SELLER MAKES NO Materials, Inc.’s direct control. THE SELLER MAKES NO
`
`equipment used commercially equipment used commercially
`
`in processing in processing
`
`these these
`
`reliable, but no reliable, but no
`
`representations, guarantees or representations, guarantees or
`
`WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WARRANTIES, EXPRESS OR IMPLIED, INCLUDING,
`
`materials, no warranties or guarantees are made as to materials, no warranties or guarantees are made as to
`
`warranties of any kind are made as to its accuracy, warranties of any kind are made as to its accuracy,
`
`BUT NOT LIMITED TO, THE IMPLIED WARRANTIES BUT NOT LIMITED TO, THE IMPLIED WARRANTIES
`
`the suitability of the suitability of
`
`the products the products
`
`
`for for
`the application the application
`
`suitability for particular applications or the results to be suitability for particular applications or the results to be
`
`OF MERCHANTABILITY AND FITNESS FOR A OF MERCHANTABILITY AND FITNESS FOR A
`
`disclosed. disclosed.
`
` Full-scale Full-scale
`
`testing and end product testing and end product
`
`obtained therefrom. The information is based on obtained therefrom. The information is based on
`
`PARTICULAR PURPOSE. Nothing contained herein is PARTICULAR PURPOSE. Nothing contained herein is
`
`performance are the responsibility of the user. Lubrizol performance are the responsibility of the user. Lubrizol
`
`laboratory work with small-scale equipment and does laboratory work with small-scale equipment and does
`
`to be considered as permission, recommendation, nor to be considered as permission, recommendation, nor
`
`Advanced Materials, Inc. shall not be liable for and the Advanced Materials, Inc. shall not be liable for and the
`
`not necessarily not necessarily
`
`indicate end product performance. indicate end product performance.
`
`as an inducement to practice any patented invention as an inducement to practice any patented invention
`
`customer assumes all risk and liability of any use of customer assumes all risk and liability of any use of
`
`Because of the variations in methods, conditions and Because of the variations in methods, conditions and
`
`without permission of the patent owner. without permission of the patent owner.
`
`handling of any material beyond Lubrizol Advanced handling of any material beyond Lubrizol Advanced
`
`
`
`For further information, please visit www.pharma.lubrizol.comFor further information, please visit www.pharma.lubrizol.com
`Lubrizol Advanced Materials, Inc. is a wholly owned subsidiary of The Lubrizol Corporation
`* Trademark owned by The Lubrizol Corporation
`© Copyright 2010 / The Lubrizol Corporation
`
`
`
`
`Aqueous Gel Viscosity
`Low
`Medium - high
`Very high
`Medium - high
`Medium - high
`Very high
`
`
`
`1
`
`AMN1020
`
`

`

`
`
`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 2 of 10
`
`Europe (Ph. Eur.)
`Carbomers
`Carbomers
`Carbomers
`Carbomers
`---
`---
`
`Japan (JPE)1
`Carboxyvinyl Polymer
`Carboxyvinyl Polymer
`Carboxyvinyl Polymer
`Carboxyvinyl Polymer
`---
`---
`
`Table 1B: Compendial Status of Polymers
`
`United States USP/NF*
`Product Trade Name
`Carbopol® 971P NF Polymer
`Carbomer Homopolymer Type A
`Carbopol® 974P NF Polymer
`Carbomer Homopolymer Type B
`Carbopol® 980 NF Polymer
`Carbomer Homopolymer Type C
`Carbopol® 5984 EP Polymer
`Carbomer Homopolymer Type B
`Carbopol® ETD 2020 NF Polymer Carbomer Interpolymer Type B
`Carbopol® Ultrez 10 NF Polymer
`Carbomer Interpolymer Type A
`* USP/NF after 2006
`
`Brookfield Viscosity of Carbopol® Polymer Dispersions
`
`Carbopol® polymers must be neutralized in order to achieve maximum viscosity. Once a neutralizer is
`added to the dispersion, thickening gradually occurs. Maximum viscosity is typically achieved at a pH of
`6.0 - 7.0.
`
`The viscosity of Carbopol® polymers will begin to decrease at a pH of 9.0 and higher. This is caused by the
`presence of excess electrolytes which affect the electrostatic repulsion of the ionized carboxylic groups. In
`order to obtain high viscosity at pH values below 5 and above 9, an increased concentration of Carbopol®
`polymer is recommended. Additionally, use of a low concentration of polymer at low pH values should be
`avoided in an effort to achieve a robust formulation.
`
`Brookfield viscosity measurements were obtained for aqueous dispersions of several Carbopol® polymers
`at concentrations of 0.2 - 2.0 wt. %. The general behavior of each polymer is shown in Figures 2 - 7 based
`on the data for one lot of each polymer. The dispersions were tested as prepared (conventionally
`represented as pH 3.0) or after neutralization with sodium hydroxide solution to pH 4.0 - 7.0. An increase
`in polymer concentration results in an increase in viscosity. In general, a pH plateau is achieved more
`readily with higher concentrations of Carbopol® polymers.
`
`
`Figure 2: Effect of pH and Concentration on the Viscosity of Carbopol® 971P NF Polymer Dispersion
`
`
`0.2% 971P NF
`0.5% 971P NF
`1.0% 971P NF
`2.0% 971P NF
`
`15000
`
`12000
`
`9000
`
`6000
`
`3000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`
`1 Based on customer request, Lubrizol certifies select lots of product against the JPE Carboxyvinyl Polymer Monograph
`
`
`
`2
`
`

`

`
`Figure 3: Effect of pH and Concentration on the Viscosity of Carbopol® 974P NF Polymer Dispersion
`
`
`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 3 of 10
`
`0.2% 974P NF
`0.5% 974P NF
`1.0% 974P NF
`2.0% 974P NF
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`
`
`
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`Figure 4: Effect of pH and Concentration on the Viscosity of Carbopol® 980 NF Polymer Dispersion
`
`
`0.2% 980 NF
`0.5% 980 NF
`1.0% 980 NF
`2.0% 980 NF
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`
`3
`
`

`

`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 4 of 10
`
`
`
`Figure 5: Effect of pH and Concentration on the Viscosity of Carbopol® 5984 EP Polymer Dispersion
`
`
`0.2% 5984 EP
`0.5% 5984 EP
`1.0% 5984 EP
`2.0% 5984 EP
`
`75000
`
`60000
`
`45000
`
`30000
`
`15000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`
`
`
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`Figure 6: Effect of pH and Concentration on the Viscosity of Carbopol® ETD 2020 NF Polymer Dispersion
`
`
`0.2% ETD 2020 NF
`0.5% ETD 2020 NF
`1.0% ETD 2020 NF
`2.0% ETD 2020 NF
`
`120000
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`
`4
`
`

`

`
`Figure 7: Effect of pH and Concentration on the Viscosity of Carbopol® Ultrez 10 NF Polymer Dispersion
`
`
`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 5 of 10
`
`0.2% Ultrez 10 NF
`0.5% Ultrez 10 NF
`1.0% Ultrez 10 NF
`2.0% Ultrez 10 NF
`
`120000
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`A comparison of the viscosity of 1.0 wt. % aqueous dispersions of several topical grades of Carbopol®
`polymers is shown in Figure 8.
`
`
`Figure 8: Effect of Polymer Type on the Viscosity of 1.0% Dispersions – Topical Products
`
`
`1.0% 980 NF
`1.0% Ultrez 10 NF
`1.0% ETD 2020 NF
`1.0% 5984 EP
`
`75000
`
`60000
`
`45000
`
`30000
`
`15000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`5
`
`

`

`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 6 of 10
`
`
`The effect of polymer type and concentration on the viscosity at pH 6.0 is represented in Figure 9 for
`several topical grades of Carbopol® polymers.
`
`Figure 9: Effect of Polymer Type and Concentration on the Viscosity at pH 6.0 – Topical Products
`
`
`980 NF
`Ultrez 10 NF
`ETD 2020 NF
`5984 EP
`
`120000
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`0
`
`0.5
`
`1.5
`1
`concentration (%)
`
`2
`
`2.5
`
`
`
`A comparison of the viscosity of oral grade Carbopol® 971P NF and 974P NF polymers at various pH levels
`and concentrations is shown in Figure 10.
`
`
`Figure 10: Effect of pH and Concentration on the Viscosity of Carbopol® 971P NF and 974P NF Polymer Dispersions
`
`0.2% 971P NF
`0.5% 971P NF
`1.0% 971P NF
`2.0% 971P NF
`0.2% 974P NF
`0.5% 974P NF
`1.0% 974P NF
`2.0% 974P NF
`
`100000
`
`80000
`
`60000
`
`40000
`
`20000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`6
`
`

`

`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 7 of 10
`
`
`Unneutralized dispersions as prepared have an approximate pH range of 2.5 - 3.5 depending on the
`polymer concentration. The unneutralized dispersions have very low viscosities as shown in Figure 11,
`especially for Carbopol® Ultrez 10 NF polymer and Carbopol® ETD 2020 NF polymers.
`
`Carbopol® Ultrez 10 NF polymer and Carbopol® ETD 2020 NF polymers provide excellent versatility in
`processing for topical formulations. Their unique dispersion performance allows the polymers to wet
`quickly, yet hydrate slowly. This minimizes agglomeration, which can be a problem if turbulent mixing is
`
`
`not available during dispersion. Compared with traditional Carbopol® polymers, Carbopol® Ultrez and ETD
`polymers provide dispersions in water that are much lower in viscosity prior to neutralization which enables
`easier handling in mixing tanks and process lines. Once the polymers are neutralized, they are highly
`efficient thickeners.
`
`Figure 11: Effect of Polymer Type and Concentration on the Viscosity of Dispersions as Prepared
`
`
`971P NF
`974P NF
`980 NF
`Ultrez 10 NF
`ETD 2020 NF
`5984 EP
`
`7500
`
`6000
`
`4500
`
`3000
`
`1500
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`0
`
`0.5
`
`1.5
`1
`concentration (%)
`
`2
`
`2.5
`
`
`In aqueous systems, inorganic bases, such as sodium hydroxide or potassium hydroxide, or low molecular
`weight amines and alkanolamines will provide satisfactory neutralization. Figure 12 shows similar
`thickening efficiencies when sodium hydroxide and triethanolamine are used to neutralize a 0.5 wt%
`aqueous dispersion of Carbopol® 980 NF polymer. No significant differences are expected if potassium
`hydroxide is used for neutralization.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7
`
`

`

`
`Figure 12: Effect of Neutralizer Type on the Viscosity of 0.5% Carbopol® 980 NF Dispersion
`
`
`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 8 of 10
`
`Sodium hydroxide (18%)
`Triethanolamine (99%)
`
`50000
`
`40000
`
`30000
`
`20000
`
`10000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`2
`
`3
`
`4
`
`5
`pH
`
`6
`
`7
`
`8
`
`
`
`Electrolytes tend to reduce the viscosity of Carbopol® polymer based gels. Therefore, a higher
`concentration of polymer should be used to minimize the viscosity loss. In general, the viscosity of lightly
`crosslinked Carbopol® polymer systems is less affected by electrolytes than highly crosslinked Carbopol®
`polymers. (Figure 13).
`
`
`Figure 13: Effect of Salt on the Viscosity of 1.0% Carbopol® 971P NF and 974P NF Polymer Dispersions at pH 6.0
`
`
`971P NF
`974P NF
`
`75000
`
`60000
`
`45000
`
`30000
`
`15000
`
`Brookfield viscosity @ 20 rpm (mPa*s)
`
`0
`
`0
`
`0.25
`
`0.5
`
`0.75
`% NaCl
`
`1
`
`1.25
`
`1.5
`
`
`
`
`
`8
`
`

`

`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 9 of 10
`
`
`Brookfield Yield Value of Carbopol® Polymer Dispersions
`
`Carbopol® polymers are unique in that they provide a wide range of viscosity profiles and have very high
`yield values, even at low concentrations. These combined features enable the formulation of oral or topical
`suspensions that are stable with low levels of polymer.
`
`Yield value is more important than viscosity when determining suspending ability of a vehicle. While
`viscosity can only slow down the rate of sedimentation, a high yield value is necessary to create permanent
`suspensions.
`
`While all Carbopol® polymers are efficient suspending agents, medium/highly crosslinked polymers have
`higher yield value than lightly crosslinked polymers such as Carbopol® 971P NF polymer (Figure 14).
`Refer to TDS-244 to calculate a theoretical yield value for a suspension.
`
`Figure 14: Effect of Polymer Type on the Brookfield Yield Value of Carbopol® Polymer Dispersions at pH 6.0
`
`
`971P NF
`974P NF
`980 NF
`Ultrez 10 NF
`ETD 2020 NF
`5984 EP
`
`20000
`
`15000
`
`10000
`
`5000
`
`Brookfield yield value (dynes/cm2)
`
`0
`
`0
`
`0.5
`
`1.5
`1
`concentration (%)
`
`2
`
`2.5
`
`
`
`The data included represents one lot of each polymer in an aqueous system. The performance of the
`polymers in other conditions (alternative vehicles, coexcipients and active pharmaceutical ingredients)
`might be different. It is recommended that key performance properties be ascertained and regulatory
`considerations be taken into account in the process of formulation development.
`
`Carbopol® polymers have been used in a variety of commercial liquid and semisolid formulations containing
`the active pharmaceutical ingredients (APIs) noted in Table 2. These APIs have been incorporated in a
`variety of dosage forms: solutions, suspensions, emulsions, lotions, creams, gels and toothpaste for
`peroral or topical administration (skin, mucosa - oral, ophthalmic, nasal, rectal, vaginal).
`
`
`
`9
`
`

`

`TDS-730
`Viscosity of Carbopol® Polymers in Aqueous Systems
`Page 10 of 10
`
`Table 2: Commercial Liquid and Semisolid Formulations Containing Carbopol® Polymers
`
`
`
`
`
`(cid:122)(cid:122) Adapalene
`(cid:122)(cid:122) Aescin
`(cid:122)(cid:122) Allantoin
`(cid:122)(cid:122) Amorolfine hydrochloride
`(cid:122)(cid:122) Azelaic acid
`(cid:122)(cid:122) Benzocaine
`(cid:122)(cid:122) Benzoyl peroxide
`(cid:122)(cid:122) Betamethasone dipropionate
`(cid:122)(cid:122) Betaxolol hydrochloride
`(cid:122)(cid:122) Brinzolamide
`(cid:122)(cid:122) Ciclopirox
`(cid:122)(cid:122) Clarithromycin
`(cid:122)(cid:122) Clindamycin
`(cid:122)(cid:122) Clobetasol propionate
`(cid:122)(cid:122) Clocortolone pivalate/ hexanoate
`(cid:122)(cid:122) Clotrimazole
`(cid:122)(cid:122) Crotamiton
`(cid:122)(cid:122) Cyclosporine
`(cid:122)(cid:122) Dexamethasone
`(cid:122)(cid:122) Dexpanthenol
`(cid:122)(cid:122) Domperidone
`(cid:122)(cid:122) Diclofenac
`(cid:122)(cid:122) Diethylamin-Salicylate
`(cid:122)(cid:122) Estradiol
`
`(cid:122)(cid:122) Estriol
`(cid:122)(cid:122) Etofenamate
`(cid:122)(cid:122) Eucalyptus oil
`(cid:122)(cid:122) Extracts (Capsicum, Arnica)
`(cid:122)(cid:122) Fluocinonide
`(cid:122)(cid:122) Fluorouracil
`(cid:122)(cid:122) Fusidic acid
`(cid:122)(cid:122) Ganciclovir
`(cid:122)(cid:122) Glycerin
`(cid:122)(cid:122) Heparin sodium
`(cid:122)(cid:122) Hydrocortisone
`(cid:122)(cid:122) Hydroquinone
`(cid:122)(cid:122) Hydroxyethylsalicylate
`(cid:122)(cid:122) Ichthammol
`(cid:122)(cid:122) Indomethacin
`(cid:122)(cid:122) Isotretinoin
`(cid:122)(cid:122) Ketoconazole
`(cid:122)(cid:122) Ketoprofen
`(cid:122)(cid:122) Lidocaine
`(cid:122)(cid:122) Menthol
`(cid:122)(cid:122) Mesalamine
`(cid:122)(cid:122) Methyl salicylate
`(cid:122)(cid:122) Metronidazole
`(cid:122)(cid:122) Miconazole nitrate
`
`(cid:122)(cid:122) Naftifine hydrochloride
`(cid:122)(cid:122) Nepafenac
`(cid:122)(cid:122) Nevirapine
`(cid:122)(cid:122) Nonoxynol 9
`(cid:122)(cid:122) Nystatin
`(cid:122)(cid:122) Octyl methoxycinnamate
`(cid:122)(cid:122) Permethrin
`(cid:122)(cid:122) Polidocanol)
`(cid:122)(cid:122) Prilocaine
`(cid:122)(cid:122) Progesterone
`(cid:122)(cid:122) Retinol palmitate
`(cid:122)(cid:122) Rimexolone
`(cid:122)(cid:122) Simethicone
`(cid:122)(cid:122) Sodium alginate
`(cid:122)(cid:122) Sodium fluoride
`(cid:122)(cid:122) Sodium hyaluronate
`(cid:122)(cid:122) Testosterone
`(cid:122)(cid:122) Thioridazine
`(cid:122)(cid:122) Timolol maleate
`(cid:122)(cid:122) Tretinoin
`(cid:122)(cid:122) Tyrothricin
`(cid:122)(cid:122) Urea
`
`
`
`
`
`
`
`10
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket